Download MendeleyStructural insights into binding specificity, efficacy and bias of a beta2AR partial agonist.
Masureel, M., Zou, Y., Picard, L.P., van der Westhuizen, E., Mahoney, J.P., Rodrigues, J.P.G.L.M., Mildorf, T.J., Dror, R.O., Shaw, D.E., Bouvier, M., Pardon, E., Steyaert, J., Sunahara, R.K., Weis, W.I., Zhang, C., Kobilka, B.K.(2018) Nat Chem Biol 14: 1059-1066
- PubMed: 30327561 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41589-018-0145-x
- Primary Citation Related Structures:
6MXT - PubMed Abstract:
Salmeterol is a partial agonist for the β 2 adrenergic receptor (β 2 AR) and the first long-acting β 2 AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol's safety and mechanism of action have both been controversial. To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound β 2 AR in complex with an active-state-stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence differences between β 1 AR and β 2 AR explain the high receptor-subtype selectivity. A structural comparison with the β 2 AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser204 5.43 and Asn293 6.55 . Mutagenesis and biophysical studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited β-arrestin recruitment for salmeterol.
- Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Organizational Affiliation:
